Last reviewed · How we verify
tetrahydrocannabinol
tetrahydrocannabinol is a Small molecule drug developed by Wageningen University. It is currently FDA-approved for Anorexia from HIV, Chemotherapy-induced nausea and vomiting. Also known as: delta-9-tetrahydrocannabinol, THC, Namisol, Dronabinol.
Tetrahydrocannabinol (THC) is a cannabinoid found in cannabis, specifically the principal psychoactive constituent of Cannabis. It is a small molecule with the chemical formula C21H30O2, typically referring to the delta-9-THC isomer.
At a glance
| Generic name | tetrahydrocannabinol |
|---|---|
| Also known as | delta-9-tetrahydrocannabinol, THC, Namisol, Dronabinol, Cannabis oil |
| Sponsor | Wageningen University |
| Target | N-arachidonyl glycine receptor, Cannabinoid receptor 2, Fatty-acid amide hydrolase 1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Anorexia from HIV
- Chemotherapy-induced nausea and vomiting
Common side effects
Key clinical trials
- EFFECTS OF A FULL SPECTRUM CANNABIS EXTRACT WITH DIFFERENT DOSES OF CBD AND THC ON THE MODULATION OF FIBROMYALGIA: A PILOT, MULTICENTER, OPEN LABEL CLINICAL TRIAL (FRIDINHA) (PHASE1, PHASE2)
- Dronabinol in Total Knee Arthroplasty (TKA) (PHASE4)
- AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT) (PHASE1)
- Effects of Dronabinol in Opioid Maintained Patients (EARLY_PHASE1)
- Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment (PHASE2)
- Dronabinol as an Adjunct for Reducing Pain (PHASE2)
- Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital (PHASE2)
- Efficacy and Safety of VER-01 in the Treatment of Patients With Radicular Chronic Low Back Pain (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tetrahydrocannabinol CI brief — competitive landscape report
- tetrahydrocannabinol updates RSS · CI watch RSS
- Wageningen University portfolio CI
Frequently asked questions about tetrahydrocannabinol
What is tetrahydrocannabinol?
What is tetrahydrocannabinol used for?
Who makes tetrahydrocannabinol?
Is tetrahydrocannabinol also known as anything else?
What development phase is tetrahydrocannabinol in?
What does tetrahydrocannabinol target?
Related
- Target: All drugs targeting N-arachidonyl glycine receptor, Cannabinoid receptor 2, Fatty-acid amide hydrolase 1
- Manufacturer: Wageningen University — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Anorexia from HIV
- Indication: Drugs for Chemotherapy-induced nausea and vomiting
- Also known as: delta-9-tetrahydrocannabinol, THC, Namisol, Dronabinol, Cannabis oil
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing